Neonatal Hypoglycemia

Definition And Physiology

• There is no universal definition for neonatal hypoglycemia.
• The World Health Organization defines hypoglycemia as a blood glucose level less than 45 mg/dL (2.2 mmol/L).
• The operational threshold for intervention is a blood glucose level less than 40 mg/dL (plasma glucose less than 45 mg/dL), irrespective of the infant's age.
• Glucose provides 60% to 70% of fetal energy needs through transplacental facilitated diffusion.
• At birth, the severing of the umbilical cord abruptly interrupts the glucose source.
• The newborn responds by initiating hepatic glycogenolysis and gluconeogenesis.
• Blood glucose levels typically fall to a low point in the first 1 to 2 hours of life.
• This transient drop is termed transitional neonatal hypoglycemia.
• Levels subsequently stabilize at 65 to 70 mg/dL by 3 to 4 hours of age.

Etiology And Classification

• Causes of neonatal hypoglycemia can be classified based on the underlying physiological mechanism.

Clinical Presentation

• Many neonates with low blood sugar values remain completely asymptomatic.
• Symptomatic hypoglycemia presents with neurogenic and neuroglycopenic signs.
• Neurogenic (autonomic) symptoms result from a sympathetic nervous discharge.
• These include jitteriness, tremors, sweating, sudden pallor, tachypnea, and tachycardia.
• Neuroglycopenic symptoms occur due to a deficient glucose supply to the brain.
• These include stupor, lethargy, apathy, cyanosis episodes, apneic spells, a weak and high-pitched cry, feeding difficulty, convulsions, and coma.

Screening Protocol

• Routine screening is not recommended in healthy, breastfed, term appropriate-for-gestational-age infants.
• Screening is mandatory for high-risk and sick neonates.

• Point-of-care devices provide rapid results but are less accurate at lower glucose levels.
• A low point-of-care value must be acted upon immediately while awaiting laboratory confirmation.
• Blood samples for laboratory testing must be collected in tubes containing glycolytic inhibitors like fluoride.

Management

%%{init: {
  "theme": "base",
  "themeVariables": {
    "lineWidth": "3px",
    "lineColor": "#4A5568"
  }
}}%%
graph TD
    %% Define Color Classes (Background, Border, Text)
    classDef critical fill:#FFEBEE,stroke:#E53935,stroke-width:3px,color:#B71C1C;
    classDef warning fill:#FFFDE7,stroke:#FBC02D,stroke-width:3px,color:#F57F17;
    classDef stable fill:#E8F5E9,stroke:#43A047,stroke-width:3px,color:#1B5E20;
    classDef neutral fill:#F7FAFC,stroke:#A0AEC0,stroke-width:3px,color:#2D3748;

    %% Node Definitions
    A([Hypoglycemia
Blood glucose < 40 mg/dl]):::critical
    
    B(Asymptomatic):::warning
    C(Symptomatic
including seizures):::critical
    
    D(20-40 mg/dl):::warning
    E(< 20 mg/dl):::critical
    F(Bolus of 2 ml/kg
10% glucose):::critical
    
    G(Trial of oral feeds):::neutral
    H(Monitor the blood
sugar after 1 hour):::neutral
    
    I(more than 40 mg/dl):::stable
    J(less than 40 mg/dl):::critical
    
    K(IV glucose infusion @ 6 mg/kg/min
Monitor hourly till euglycemic
and then 6 hourly):::warning
    
    L(Frequent feeds):::stable
    M(Monitor blood
sugar 6 hourly):::stable
    N(Stop after 48 hours):::stable
    O(Before discharge
ensure that there is
no feeding difficulty):::stable
    
    P(Blood sugar > 50 mg/dL):::stable
    Q(Blood sugar < 50 mg/dl):::critical
    
    R(Stable for 24 hours on
IV fluids; 2 values of
blood sugar > 50 mg/dl):::stable
    S(Weaning by 2 mg/kg/min every
6 hours; ↑ oral feeds;
Monitoring to continue 6 hourly):::stable
    T(Stop IV fluids when
the rate is 4 mg/kg/min
and the infant is stable):::stable
    U(Stop monitoring when
2 values are more than
50 on full oral feeds):::stable
    
    V(Increase glucose
by 2 mg/kg/min till
euglycemia):::warning
    W(Increase till the glucose
infusion rate is
> 12 mg/kg/min):::critical
    X("Refer to specialist
center for further
investigation(s)"):::critical
    Y("Hydrocortisone
Diazoxide (not in SGA)
Glucagon (not in SGA)
Octreotide"):::critical

    %% Flow/Connections
    A --> B
    A --> C
    
    B --> D
    B --> E
    C --> F
    
    D --> G
    G --> H
    H --> I
    H --> J
    
    I --> L
    L --> M
    M --> N
    N --> O
    
    E --> K
    F --> K
    J --> K
    
    K --> P
    K --> Q
    
    P --> R
    R --> S
    S --> T
    T --> U
    
    Q --> V
    V --> W
    W --> X
    X --> Y

Asymptomatic Hypoglycemia

• The primary approach is to initiate feeding, preferably direct breastfeeding.
• If the infant cannot suck, expressed breast milk should be given by spoon or paladai.
• Buccal dextrose gel (200 mg/kg) can be applied to the dried buccal mucosa, followed by feeding.
• Blood glucose must be rechecked 30 minutes after feeding or gel administration.
• Intravenous fluids are considered if glucose levels remain very low despite feeding.

Symptomatic Hypoglycemia

• Symptomatic infants must be treated immediately with intravenous fluids.
• A mini bolus of 2 mL/kg of 10% dextrose (200 mg/kg) is administered intravenously over 1 minute.
• This is followed by a continuous intravenous glucose infusion at a rate of 6 to 8 mg/kg/minute.
• Blood glucose levels are rechecked after 30 minutes.
• If blood glucose remains below 50 mg/dL, the glucose infusion rate is increased in steps of 2 mg/kg/minute.
• The maximum standard glucose infusion rate is 12 mg/kg/minute.
• The glucose infusion rate in mg/kg/minute is calculated as: (Dextrose percentage × volume in mL/kg/day) / 144.

Persistent Or Refractory Hypoglycemia

• Refractory hypoglycemia is defined by a glucose infusion requirement exceeding 12 mg/kg/minute.
• Hyperinsulinism is the most common cause of persistent hypoglycemia.
• A critical sample must be drawn at the time of hypoglycemia (blood glucose less than 40 mg/dL).
• The critical sample assay includes glucose, insulin, cortisol, growth hormone, beta-hydroxybutyrate, and free fatty acids.
• Detectable insulin (greater than 2 mIU/L) with low free fatty acids and low ketones confirms hyperinsulinism.
• Pharmacologic treatments for refractory cases include hydrocortisone, diazoxide, and octreotide.

Complications And Prognosis

• Symptomatic and prolonged hypoglycemia is associated with a high risk of neurodevelopmental disability.
• The occipital cortex and subcortical white matter are the typical brain regions injured by hypoglycemia.
• Affected children may exhibit visuo-motor problems, poor executive function, low literacy, and numeracy issues in later childhood.
• Magnetic resonance imaging performed at 4 to 6 weeks helps estimate the extent of hypoglycemic brain injury.